Omega Therapeutics, Inc.
CIK 0001850838
Revenue (TTM)
$144K
Q3 Nov 2024
Net Income (TTM)
−$75.13M
+5.1% YoY
Q3 Nov 2024
EPS Diluted (TTM)
−$1.36
+15.9% YoY
Q3 Nov 2024
Gross Margin
—
Q3 Nov 2024
Operating Margin
-53,023.6%
Q3 Nov 2024
Net Margin
-52,170.8%
Q3 Nov 2024
Free Cash Flow (TTM)
−$76.68M
Q3 Nov 2024
Cash
$30.38M
Q3 Nov 2024
Total Debt
$15.59M
Q3 Nov 2024
Shares Outstanding
55.37M sh
Q3 Nov 2024
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.